Collplant Biotechnologies Company Leadership

CLGN Stock  USD 5.18  0.07  1.33%   
Collplant Biotechnologies employs about 75 people. The company is managed by 23 executives with a total tenure of roughly 144 years, averaging almost 6.0 years of service per executive, having 3.26 employees per reported executive. Analysis of Collplant Biotechnologies' management performance can provide insight into the firm performance.
Yehiel Tal  CEO
CEO Director
Jonathan Rigby  Chairman
Chairman of the Board
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collplant Biotechnologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.

Collplant Biotechnologies' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Collplant Biotechnologies' future performance. Based on our forecasts, it is anticipated that Collplant will maintain a workforce of about 80 employees by May 2024.
 
Covid

Collplant Biotechnologies Management Team Effectiveness

The company has return on total asset (ROA) of (0.1306) % which means that it has lost $0.1306 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2316) %, meaning that it created substantial loss on money invested by shareholders. Collplant Biotechnologies' management efficiency ratios could be used to measure how well Collplant Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 16th of April 2024, Return On Tangible Assets is likely to drop to -0.22. In addition to that, Return On Capital Employed is likely to drop to -0.26. At this time, Collplant Biotechnologies' Other Current Assets are very stable compared to the past year. As of the 16th of April 2024, Intangible Assets is likely to grow to about 278.5 K, while Total Assets are likely to drop about 18.2 M.
As of the 16th of April 2024, Common Stock Shares Outstanding is likely to grow to about 12 M, while Net Loss is likely to drop (20.4 M).

Collplant Biotechnologies Workforce Comparison

Collplant Biotechnologies is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 2,628. Collplant Biotechnologies holds roughly 75.0 in number of employees claiming about 2.85% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.64) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (16.95) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $16.95.

Collplant Biotechnologies Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Collplant Biotechnologies Price Series Summation is a cross summation of Collplant Biotechnologies price series and its benchmark/peer.

Collplant Biotechnologies Notable Stakeholders

A Collplant Biotechnologies stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Collplant Biotechnologies often face trade-offs trying to please all of them. Collplant Biotechnologies' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Collplant Biotechnologies' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Yehiel TalCEO DirectorProfile
Jonathan RigbyChairman of the BoardProfile
David TsurChairman of the BoardProfile
Philippe BensimonVice President-Regulation & Quality ControlProfile
Shomrat ShurtzVice President - CommercializationProfile
Eran RotemVice President - FinanceProfile
Ilana BelzerVice President - OperationsProfile
Nadav OrrVice President - Research & DevelopmentProfile
Abraham HavronIndependent DirectorProfile
Adi GoldinDirectorProfile
Elan PennExternal DirectorProfile
Talya ZavchonFinance DirectorProfile
Gili HartExternal DirectorProfile
Scott BurellIndependent DirectorProfile
Michal RoytmanVP MarketingProfile
Pr ShoseyovFounder ScientistProfile
Oded ShoseyovChief Scientific OfficerProfile
Elana GazalVice DevelopmentProfile
Revital MandilLevinChief Business Development OfficerProfile
Oren FahimipoorVice OperationsProfile
Dana ErlichInternal AuditorProfile
Eran CPADeputy CFOProfile
Hadas HorowitzVice ResourcesProfile

About Collplant Biotechnologies Management Performance

The success or failure of an entity such as Collplant Biotechnologies often depends on how effective the management is. Collplant Biotechnologies management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Collplant management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Collplant management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.21)(0.22)
Return On Capital Employed(0.24)(0.26)
Return On Assets(0.21)(0.22)
Return On Equity(0.25)(0.26)
The data published in Collplant Biotechnologies' official financial statements usually reflect Collplant Biotechnologies' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Collplant Biotechnologies. For example, before you start analyzing numbers published by Collplant accountants, it's critical to develop an understanding of what Collplant Biotechnologies' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Collplant Biotechnologies' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Collplant Biotechnologies' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Collplant Biotechnologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Collplant Biotechnologies. Please utilize our Beneish M Score to check the likelihood of Collplant Biotechnologies' management manipulating its earnings.

Collplant Biotechnologies Workforce Analysis

Traditionally, organizations such as Collplant Biotechnologies use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Collplant Biotechnologies within its industry.

Collplant Biotechnologies Manpower Efficiency

Return on Collplant Biotechnologies Manpower

Revenue Per Employee146.1K
Revenue Per Executive476.5K
Net Loss Per Employee93.6K
Net Loss Per Executive305.2K
Working Capital Per Employee330.3K
Working Capital Per Executive1.1M
When determining whether Collplant Biotechnologies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Collplant Biotechnologies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Collplant Biotechnologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Collplant Biotechnologies Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collplant Biotechnologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.
Note that the Collplant Biotechnologies information on this page should be used as a complementary analysis to other Collplant Biotechnologies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Complementary Tools for Collplant Stock analysis

When running Collplant Biotechnologies' price analysis, check to measure Collplant Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Collplant Biotechnologies is operating at the current time. Most of Collplant Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Collplant Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Collplant Biotechnologies' price. Additionally, you may evaluate how the addition of Collplant Biotechnologies to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Money Managers
Screen money managers from public funds and ETFs managed around the world
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Commodity Directory
Find actively traded commodities issued by global exchanges
Bonds Directory
Find actively traded corporate debentures issued by US companies
Stocks Directory
Find actively traded stocks across global markets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Is Collplant Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collplant Biotechnologies. If investors know Collplant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collplant Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.62)
Revenue Per Share
0.962
Quarterly Revenue Growth
4.155
Return On Assets
(0.13)
Return On Equity
(0.23)
The market value of Collplant Biotechnologies is measured differently than its book value, which is the value of Collplant that is recorded on the company's balance sheet. Investors also form their own opinion of Collplant Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Collplant Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collplant Biotechnologies' market value can be influenced by many factors that don't directly affect Collplant Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collplant Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Collplant Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collplant Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.